Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells

Endocrine

Volumn 36, Issue 1, 2009, Pages 60-69

  Luo, Zhaofan ^a   Zhang, Ying ^a   Li, Fangping ^a   He, Juan ^a   Ding, Helin ^a   Yan, Li ^a   Cheng, Hua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

AMPK; Diabetes; HepG2; Insulin; Resistin; SiRNA

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER 2; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN RECEPTOR SUBSTRATE; IRS2 PROTEIN, HUMAN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PRKAA2 PROTEIN, HUMAN; PROTEIN KINASE B; RESISTIN; RETN PROTEIN, HUMAN; SACCHARIC ACID; SLC2A2 PROTEIN, HUMAN; SMALL INTERFERING RNA; SOCS3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING;

ARTICLE; BIOSYNTHESIS; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION; GLUCARIC ACID; GLUCOSE TRANSPORTER TYPE 2; GLUCOSE-6-PHOSPHATASE; GLYCOGEN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LIVER NEOPLASMS; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RESISTIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 70349570571     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-009-9198-7     Document Type: Article

References (50)

1. B.B. Kahn, J.S. Flier, Obesity and insulin resistance. J. Clin. Invest. 106, 473-481 (2000)
2. J.S. Flier, Obesity wars: Molecular progress confronts an expanding epidemic. Cell 116, 337-350 (2004)
3. V. Mohamed-Ali, J.H. Pinkney, S.W. Coppack, Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. Relat. Metab. Disord. 22, 1145-1158 (1998)
4. P. Trayhurn, J.H. Beattie, Physiological role of adipose tissue: White adipose tissue as an endocrine and secretory organ. Proc. Nutr. Soc. 60, 329-339 (2001)
5. I.N. Holcomb, R.C. Kabakoff, B. Chan, T.W. Baker, A. Gurney, W. Henzel, C. Nelson, H.B. Lowman, B.D. Wright, N.J. Skelton, G.D. Frantz, D.B. Tumas, F.V. Peale Jr., D.L. Shelton, C.C. Hebert, FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J. 19, 4046-4055 (2000)
6. K.H. Kim, K. Lee, Y.S. Moon, H.S. Sul, A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J. Biol. Chem. 276, 11252-11256 (2001)
7. C.M. Steppan, S.T. Bailey, S. Bhat, E.J. Brown, R.R. Banerjee, C.M. Wright, H.R. Patel, R.S. Ahima, M.A. Lazar, The hormone resistin links obesity to diabetes. Nature 409, 307-312 (2001)
8. E.D. Muse, S. Obici, S. Bhanot, B.P. Monia, R.A. McKay, M.W. Rajala, P.E. Scherer, L. Rossetti, Role of resistin in diet-induced hepatic insulin resistance. J. Clin. Invest. 114, 232-239 (2004)
9. R.R. Banerjee, S.M. Rangwala, J.S. Shapiro, A.S. Rich, B. Rhoades, Y. Qi, J. Wang, M.W. Rajala, A. Pocai, P.E. Scherer, C.M. Steppan, R.S. Ahima, S. Obici, L. Rossetti, M.A. Lazar, Regulation of fasted blood glucose by resistin. Science 303, 1195-1198 (2004)
10. M. Gawa-Yamauchi, J.E. Bovenkerk, B.E. Juliar, W. Watson, K. Kerr, R. Jones, Q. Zhu, R.V. Considine, Serum resistin (FIZZ3) protein is increased in obese humans. J. Clin. Endocrinol. Metab. 88, 5452-5455 (2003)
11. S.R. Smith, F. Bai, C. Charbonneau, L. Janderova, G. Argyropoulos, A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 52, 1611-1618 (2003)
12. J.H. Lee, J.L. Chan, N. Yiannakouris, M. Kontogianni, E. Estrada, R. Seip, C. Orlova, C.S. Mantzoros, Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: Cross-sectional and interventional studies in normal, insulinresistant, and diabetic subjects. J. Clin. Endocrinol. Metab. 88, 4848-4856 (2003)
13. L.K. Heilbronn, J. Rood, L. Janderova, J.B. Albu, D.E. Kelley, E. Ravussin, S.R. Smith, Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J. Clin. Endocrinol. Metab. 89, 1844-1848 (2004)
14. S. Ghosh, A.K. Singh, B. Aruna, S. Mukhopadhyay, N.Z. Ehtesham, The genomic organization of mouse resistin reveals major differences from the human resistin: Functional implications. Gene. 305, 27-34 (2003)
15. I. Nagaev, U. Smith, Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem. Biophys. Res. Commun. 285, 561-564 (2001)
16. J.N. Fain, P.S. Cheema, S.W. Bahouth, H.M. Lloyd, Resistin release by human adipose tissue explants in primary culture. Biochem. Biophys. Res. Commun. 300, 674-678 (2003)
17. D.G. Hardie, The AMP-activated protein kinase pathway-new players upstream and downstream. J. Cell Sci. 117, 5479-5487 (2004)
18. D. Carling, The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem. Sci. 29, 18-24 (2004)
19. B.E. Kemp, D. Stapleton, D.J. Campbell, Z.P. Chen, S. Murthy, M. Walter, A. Gupta, J.J. Adams, F. Katsis, D.B. van, I.G. Jennings, T. Iseli, B.J. Michell, L.A. Witters, AMP-activated protein kinase, super metabolic regulator. Biochem. Soc. Trans. 31, 162-168 (2003)
20. D. Stapleton, E. Woollatt, K.I. Mitchelhill, J.K. Nicholl, C.S. Fernandez, B.J. Michell, L.A. Witters, D.A. Power, G.R. Sutherland, B.E. Kemp, AMP-activated protein kinase isoenzyme family: Subunit structure and chromosomal location. FEBS Lett. 409, 452-456 (1997)
21. M.S. Kim, Y.K. Pak, P.G. Jang, C. Namkoong, Y.S. Choi, J.C. Won, K.S. Kim, S.W. Kim, H.S. Kim, J.Y. Park, Y.B. Kim, K.U. Lee, Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat. Neurosci. 9, 901-906 (2006)
22. B. Viollet, F. Andreelli, S.B. Jorgensen, C. Perrin, A. Geloen, D. Flamez, J. Mu, C. Lenzner, O. Baud, M. Bennoun, E. Gomas, G. Nicolas, J.F. Wojtaszewski, A. Kahn, D. Carling, F.C. Schuit, M.J. Birnbaum, E.A. Richter, R. Burcelin, S. Vaulont, The AMPactivated protein kinase alpha2 catalytic subunit controls wholebody insulin sensitivity. J. Clin. Invest. 111, 91-98 (2003)
23. Y.C. Long, J.R. Zierath, AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Invest. 116, 1776-1783 (2006)
24. K. Ravnskjaer, M. Boergesen, L.T. Dalgaard, S. Mandrup, Glucose-induced repression of PPARalpha gene expression in pancreatic beta-cells involves PP2A activation and AMPK inactivation. J. Mol. Endocrinol. 36, 289-299 (2006)
25. D.R. Alessi, C.P. Downes, The role of PI 3-kinase in insulin action. Biochim. Biophys. Acta 1436, 151-164 (1998)
26. P.J. Coffer, J. Jin, J.R. Woodgett, Protein kinase B (c-Akt): A multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J. 335(Pt 1), 1-13 (1998)
27. L.C. Cantley, The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 (2002)
28. P. Cohen, D.R. Alessi, D.A. Cross, PDK1, one of the missing links in insulin signal transduction? FEBS Lett. 410, 3-10 (1997)
29. S.R. Datta, A. Brunet, M.E. Greenberg, Cellular survival: A play in three Akts. Genes Dev. 13, 2905-2927 (1999)
30. E.L. Whiteman, H. Cho, M.J. Birnbaum, Role of Akt/protein kinase B in metabolism. Trends Endocrinol. Metab. 13, 444-451 (2002)
31. B.D. Manning, L.C. Cantley, AKT/PKB signaling: Navigating downstream. Cell 129, 1261-1274 (2007)
32. P.G. McTernan, F.M. Fisher, G. Valsamakis, R. Chetty, A. Harte, C.L. McTernan, P.M. Clark, S.A. Smith, A.H. Barnett, S. Kumar, Resistin and type 2 diabetes: Regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J. Clin. Endocrinol. Metab. 88, 6098-6106 (2003)
33. P.G. McTernan, C.M. Kusminski, S. Kumar, Resistin. Curr. Opin. Lipidol. 17, 170-175 (2006)
34. L. Zhou, H. Sell, K. Eckardt, Z. Yang, J. Eckel, Conditioned medium obtained from in vitro differentiated adipocytes and resistin induce insulin resistance in human hepatocytes. FEBS Lett. 581, 4303-4308 (2007)
35. C.M. Taniguchi, K. Ueki, R. Kahn, Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J. Clin. Invest. 115, 718-727 (2005)
36. K. Nakamaru, K. Matsumoto, T. Taguchi, M. Suefuji, Y. Murata, M. Igata, J. Kawashima, T. Kondo, H. Motoshima, K. Tsuruzoe, N. Miyamura, T. Toyonaga, E. Araki, AICAR, an activator of AMP-activated protein kinase, down-regulates the insulin receptor expression in HepG2 cells. Biochem. Biophys. Res. Commun. 328, 449-454 (2005)
37. A. Woods, D. Zzout-Marniche, M. Foretz, S.C. Stein, P. Lemarchand, P. Ferre, F. Foufelle, D. Carling, Characterization of the role of AMP-activated protein kinase in the regulation of glucoseactivated gene expression using constitutively active and dominant negative forms of the kinase. Mol. Cell. Biol. 20, 6704-6711 (2000)
38. M. Zang, A. Zuccollo, X. Hou, D. Nagata, K. Walsh, H. Herscovitz, P. Brecher, N.B. Ruderman, R.A. Cohen, AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem. 279, 47898-47905 (2004)
39. S.M. Rangwala, A.S. Rich, B. Rhoades, J.S. Shapiro, S. Obici, L. Rossetti, M.A. Lazar, Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53, 1937-1941 (2004)
40. C.M. Steppan, J. Wang, E.L. Whiteman, M.J. Birnbaum, M.A. Lazar, Activation of SOCS-3 by resistin. Mol. Cell. Biol. 25, 1569-1575 (2005)
41. L. Patel, A.C. Buckels, I.J. Kinghorn, P.R. Murdock, J.D. Holbrook, C. Plumpton, C.H. Macphee, S.A. Smith, Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem. Biophys. Res. Commun. 300, 472-476 (2003)
42. N. Silswal, A.K. Singh, B. Aruna, S. Mukhopadhyay, S. Ghosh, N.Z. Ehtesham, Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaBdependent pathway. Biochem. Biophys. Res. Commun. 334, 1092-1101 (2005)
43. A. Niederwanger, M. Kranebitter, C. Ciardi, T. Tatarczyk, J.R. Patsch, M.T. Pedrini, Resistin impairs basal and insulin-induced glycogen synthesis by different mechanisms. Mol. Cell. Endocrinol. 263, 112-119 (2007)
44. B. Viollet, M. Foretz, B. Guigas, S. Horman, R. Dentin, L. Bertrand, L. Hue, F. Andreelli, Activation of AMP-activated protein kinase in the liver: A new strategy for the management of metabolic hepatic disorders. J. Physiol. 574, 41-53 (2006)
45. M.C. Towler, D.G. Hardie, AMP-activated protein kinase in metabolic control and insulin signaling. Circ. Res. 100, 328-341 (2007)
46. A.Y. Viana, H. Sakoda, M. Anai, M. Fujishiro, H. Ono, A. Kushiyama, Y. Fukushima, Y. Sato, Y. Oshida, Y. Uchijima, H. Kurihara, T. Asano, Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. Diabetes Res. Clin. Pract. 73, 135-142 (2006)
47. P.A. Lochhead, I.P. Salt, K.S. Walker, D.G. Hardie, C. Sutherland, 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 49, 896-903 (2000)
48. J.J. Senn, P.J. Klover, I.A. Nowak, T.A. Zimmers, L.G. Koniaris, R.W. Furlanetto, R.A. Mooney, Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 278, 13740-13746 (2003)
49. B. Emanuelli, P. Peraldi, C. Filloux, C. Chavey, K. Freidinger, D.J. Hilton, G.S. Hotamisligil, O.E. Van, SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factoralpha in the adipose tissue of obese mice. J. Biol. Chem. 276, 47944-47949 (2001)
50. L. Rui, M. Yuan, D. Frantz, S. Shoelson, M.F. White, SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277, 42394-42398 (2002)